Efficacy and Safety of Intraparenchymal Portal Vein Covered Stents in Treating Portal Hypertension and Its Complications

Inclusion Criteria: * Age 18-75 years (inclusive); male or non-pregnant female. * Diagnosed with cirrhosis and associated complications of portal hypertension (such as esophageal and gastric variceal bleeding, refractory ascites), and meeting the consensus recommendations for TIPS indications (see Appendix 5). * Participants must understand the purpose of the trial, voluntarily participate, sign an informed consent form, and be willing to complete the follow-up according to the project requirements. Exclusion Criteria: * Severe right heart failure, congestive heart failure (LVEF \< 40%), or severe valvular heart dysfunction. * Uncontrolled systemic infection or inflammation. * Persistent moderate to severe pulmonary hypertension after treatment (tricuspid regurgitant peak velocity \> 3.4 m/s or pulmonary artery systolic pressure \> 50 mmHg). * Patients in hepatic encephalopathy coma or comatose phase (West Haven Criteria Stage III, IV). * Severe liver dysfunction, Child-Pugh score \> 13, or MELD score \> 18. * Serum creatinine (Scr) \> 178 umol/L or on dialysis. * Stage IIIa or higher liver malignancy. * Budd-Chiari syndrome, hepatic veno-occlusive disease, or obstructive cholestasis. * Polycystic liver disease. * Unrectifiable coagulopathy (INR \> 5 or PLT count \< 20 x 10\^9/L). * Main portal vein thrombosis occupying \> 50% of the lumen area or cavernous transformation of the portal vein. * Previous TIPS procedure or planned liver transplantation within a year. * Allergy to contrast agents or nickel-titanium alloys. * Life expectancy less than 1 year. * Participation in other drug or medical device clinical trials within three months before screening. * Other conditions deemed by the researcher as unsuitable for participation in this clinical trial.